Physician profile
Michael Salama
NPI 1518306281
$4,521.51
in general payments reported to CMS, 2019-2025
23 companies · $174 in 2025
The $174 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $720 · 2020: $374 · 2021: $1,756 · 2022: $124 · 2023: $129 · 2024: $1,244 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $872 · Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $872.01 |
| Food and Beverage | $674.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,178.16 | 2021 | |
| Philips North America LLC | $1,046.85 | 2022-2024 | (Bh4) Igt Devices Undivided, (P88) Igt Devices Fm |
| Boston Scientific Corporation | $444.63 | 2019-2021 | |
| Astellas Pharma US INC | $348.50 | 2019-2020 | |
| Abiomed | $300.45 | 2024-2025 | Impella |
| Abbott Laboratories | $189.11 | 2021-2023 | Amplatzer |
| Janssen Pharmaceuticals, INC | $170.98 | 2019-2024 | Xarelto |
| Medtronic, INC. | $154.24 | 2021 | |
| Amgen INC. | $127.67 | 2019-2020 | |
| Medtronic Vascular, INC. | $126.79 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $78.72 | 2019-2021 | |
| Terumo Medical Corporation | $60.00 | 2023-2024 | Azur Cx Detachable, Optitorque |
| Inari Medical, INC. | $44.43 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $38.64 | 2019 | |
| Alnylam Pharmaceuticals INC. | $36.86 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.56 | 2019-2021 | |
| Chiesi USA, INC. | $27.90 | 2020-2021 | |
| Pfizer INC. | $26.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.35 | 2020 | |
| Cordis US Corp. | $20.40 | 2025 | Mynx Control |
| E.R. Squibb & Sons, L.L.C. | $18.54 | 2019 | |
| Akcea Therapeutics, INC. | $13.12 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Salama listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.